BIHC

BIHC is a TNF blocker with anti-inflammatory activity. BIHC can significantly inhibit the proliferation of hepatocellular carcinoma (HCC) cells and exhibits potent cytotoxicity against the HepG2 cell line, capable of inducing cell apoptosis , while demonstrating relatively low toxicity towards normal hepatocytes. Additionally, BIHC can be used for research on inflammatory bowel disease (IBD) [1].

Product Specifications

CAS Number

[1642826-40-1]

UNSPSC

12352005

Target

Apoptosis; Bcl-2 Family; IFNAR; Interleukin Related; NF-κB; TNF Receptor

Related Pathways

Apoptosis; Immunology/Inflammation; NF-κB

Applications

Cancer-Kinase/protease

Field of Research

Inflammation/Immunology

Purity

98.0

Smiles

O=C1OC2=C(C(O)=C1C(C3=C(O)C4=C(C=CC=C4)OC3=O)C5=C(Cl)N=C(CCCC)N5)C=CC=C2

Molecular Formula

C26H21ClN2O6

Molecular Weight

492.91

References & Citations

[1]Keerthy H K, Mohan C D, Siveen K S, et al. Novel synthetic biscoumarins target tumor necrosis factor-α in hepatocellular carcinoma in vitro and in vivo[J]. Journal of Biological Chemistry, 2014, 289 (46) : 31879-31890.